Filing summary
Entity mismatch: The request identifies Cibus, Inc., but the supplied Form 10-Q is for Calyxt, Inc. (NASDAQ: CLXT). The filing does not identify Cibus as the registrant. Confirm that this is the intended filing before relying on this summary.
Business context and reporting period
This unaudited Form 10-Q covers the quarter and six months ended June 30, 2022, and was filed August 4, 2022. Calyxt describes itself as an early-stage plant-based synthetic biology company, developing its PlantSpring platform and BioFactory production system for customer applications, while also pursuing technology and agricultural-trait licensing. Cellectis owned 51.3% of Calyxt’s issued and outstanding common stock as of June 30, 2022.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $41,000 | $11.88 million | $73,000 | $16.282 million |
| Gross profit (loss) | $41,000 | $353,000 | $73,000 | $(1.990) million |
| Operating expenses | $6.806 million | $6.337 million | $12.927 million | $13.675 million |
| Net loss | $(2.485) million | $(4.807) million | $(8.104) million | $(14.835) million |
| Net loss per share | $(0.05) | $(0.13) | $(0.18) | $(0.40) |
| Adjusted EBITDA loss | $(4.815) million | $(5.814) million | $(9.769) million | $(12.641) million |
Revenue was nearly eliminated after the late-2021 wind-down of the soybean product line; 2022 revenue primarily came from a customer development agreement for a palm-oil alternative. Despite nominal revenue, reported gross profit equaled revenue because cost of goods sold was zero in 2022. The company remained loss-making, and operating cash use remained substantial.
- Cash and liquidity: Cash, cash equivalents, and restricted cash totaled $11.914 million at June 30, 2022, including $0.598 million of restricted cash. Cash and cash equivalents alone were $11.316 million. Current liabilities were $4.501 million.
- Cash flow, six months: Operating activities used $11.276 million; investing activities used $1.289 million; financing activities provided $10.058 million. Cash, cash equivalents, and restricted cash fell by $2.507 million from year-end 2021.
- Debt and lease obligations: Financing lease obligations totaled $283,000 at June 30, 2022, including $246,000 current. Operating lease obligations were $13.652 million non-current; the company reported a $13.855 million operating lease right-of-use asset. The filing does not report material conventional borrowing.
- Equity financing: The February follow-on offering generated approximately $10.0 million net proceeds. The company issued common shares and warrants; 7.76 million common warrants remained outstanding at June 30, exercisable at $1.41 per share beginning August 23, 2022. Common warrants are recorded as a liability and remeasured at fair value.
Material changes versus prior comparable periods
- Revenue fell by $11.839 million in Q2 and $16.209 million in the first half, primarily reflecting the soybean product-line wind-down.
- Q2 net loss improved by $2.322 million and first-half net loss by $6.731 million. The reported improvement included non-operating gains from remeasurement of the common-warrant liability as the stock price declined; these gains are non-cash and may reverse.
- First-half operating cash use was approximately flat year over year. Management cautioned that 2022 operating cash use could exceed 2021 because the working-capital benefit from winding down the soybean business had ended.
- Adoption of lease accounting on January 1, 2022 resulted in recognition of operating lease assets and liabilities of approximately $14.1 million at adoption and an $832,000 cumulative equity adjustment. It did not affect reported operating results or cash flows.
- Common shares outstanding increased from 38.774 million at December 31, 2021 to 46.716 million at June 30, 2022, reflecting the offering and exercise of pre-funded warrants, among other share activity.
Outlook, risks, and unusual items
- Going concern: Management stated that available cash, the offering proceeds, planned spending reassessment, and continued investment in BioFactory would fund operations into early 2023. It concluded that substantial doubt exists about the company’s ability to continue as a going concern because additional capital is needed to support its plan for 12 months or more from the filing date. Further financing may be unavailable or dilutive; failure to obtain funding could require significant reductions, delays, or cessation of operations.
- Business milestones: Calyxt had evaluated 95 customer-submitted chemistries, 31 of which met its target product-profile criteria. It was negotiating term sheets for selected development projects and targeted two to four customer-driven compounds for development by year-end 2022. A pilot project for a large consumer-products company was expected to yield an engineered solution in early 2023. A contracted palm-oil-alternative soybean project was described as on track for completion in Q1 2024, with development costs funded by the customer.
- Licensing and manufacturing: The company reported term-sheet discussions for technology and trait licenses and discussions with potential infrastructure partners, but these were not reported as completed agreements. It targeted execution of licenses during 2022.
- Nasdaq listing: Calyxt received a May 17, 2022 notice that it did not meet Nasdaq’s $1.00 minimum bid-price requirement after 30 consecutive business days below that level. Stockholders approved a reverse-split authorization of 2-for-1 to 10-for-1; the filing cautions that a split might not raise or sustain the market price and could reduce liquidity.
- Key risks: Dependence on additional financing, execution and scaling of BioFactory, customer adoption and development timelines, competition, supply-chain and facility disruptions, regulatory and intellectual-property risks, and volatile share-price effects on warrant remeasurement. The filing reported no material pending legal proceedings and no material COVID-19 operating impact in the first half.
Important facts for investors to verify
- Confirm whether the intended issuer is Calyxt, Inc. (CLXT) or Cibus, Inc.; the supplied filing is for Calyxt.
- Assess the going-concern warning, stated early-2023 cash runway, operating cash burn, and the company’s financing capacity and applicable offering limits.
- Track actual customer contracts, license execution, pilot results, BioFactory scale-up, and timing of any revenue relative to management’s stated targets.
- Review the Nasdaq bid-price deficiency and any subsequent compliance actions, including whether a reverse stock split was implemented.
- Evaluate dilution and potential warrant-related cash obligations, as well as the effect of warrant fair-value changes on reported earnings.
- Distinguish GAAP results from non-GAAP adjusted net loss and Adjusted EBITDA; reported earnings improvement included a substantial warrant remeasurement gain.